Carregant...
GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
BACKGROUND: The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling o...
Guardat en:
| Publicat a: | BMC Med Inform Decis Mak |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7469913/ https://ncbi.nlm.nih.gov/pubmed/32580715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12911-020-01149-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|